NOV 15, 2017 10:00 AM PST

WEBINAR: Characterization of immune checkpoint expression & infiltrating immune cells in TME by RNAscope ISH

Speaker
  • Scientist, Advanced Cell Diagnostics
    Biography
      Currently I am a scientist in R&D at Advanced Cell Diagnostics (ACD) in Newark, California. In the applications group we manage numerous projects within the ACD R&D laboratories and with collaborators from around the globe to demonstrate new and exciting applications of the RNAscope and BaseScope technologies and their ability to detect RNA biomarkers with single-molecule sensitivity and single-cell resolution within the morphological context.

      Prior to joining ACD, I completed my postdoctoral studies in cancer biology at the University of California San Francisco. I received my Ph.D. in cognitive and molecular neurosciences from the University of Leuven (Belgium) after completing a one-year visiting scientist position focusing on medical entomology at the University of Florida. Prior, I graduated as bio-engineer in cell-and gene biotechnology from the University of Leuven with a 6-month international exchange program at the University of Milan (Italy).

    Abstract

    DATE: November 15, 2017
    TIME: 10:00AM PT

    Interactions between tumor and immune cells in the tumor microenvironment (TME) play a key role in tumor progression and treatment response, with accumulating evidence indicating a crucial role for tumor infiltrating immune cells. Although infiltrating T cells have been correlated with improved clinical outcome, they are ineffective in eradicating tumors due to their inhibition by immune checkpoint molecules. 


    Immune checkpoint inhibitors have demonstrated therapeutic efficacy and durable response for several tumor types, including NSCLC. However, the majority of patients are resistant or relapse after initial response. Characterizing the TME for checkpoint expression with single-cell and spatial resolution can provide critical insight into new immunotherapeutic strategies and identify new predictive biomarkers for stratifying patients most likely to benefit from immunotherapies. 


    In addition, the visualization of immunosuppressive factors that contribute to tumor evasion by recruiting and modulating regulatory T cells and myeloid-derived cells could offer a more comprehensive understanding of the TME.
    In this webinar, we will highlight the in situ visualization of the following targets at the single-cell level in the TME of NSCLC and ovarian cancer archived FFPE tissue samples using the highly specific and sensitive in situ hybridization assay RNAscope®: - Expression and co-expression profiles of therapeutic checkpoint targets including PD1, PD-L1, PD-L2, TIM3, LAG3, CTLA-4 and GITR in individual infiltrating immune cells within the morphological tissue context.
    - Immune infiltration and state of lymphoid and myeloid cells in the TME by detecting key functional molecules, FOXP3, IFNg, CXCL10, and CCL22 combined with cell lineage markers CD4, CD8, CD68, and CD163.

     


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    APR 21, 2021 5:00 PM CEST
    APR 21, 2021 5:00 PM CEST
    Date: April 21, 2021 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Spatial Answers Trilogy - Spatial Answers in Immunology Immunology Researchers share their Spatial Discoveries in SARS-C...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    NOV 15, 2017 10:00 AM PST

    WEBINAR: Characterization of immune checkpoint expression & infiltrating immune cells in TME by RNAscope ISH


    Specialty

    Cancer Research

    Biomarkers

    Immunology

    Cancer Therapeutics

    Cell Biology

    Molecular Biology

    Cancer Diagnostics

    Oncology

    Biotechnology

    Molecular Diagnostics

    Clinical Research

    Clinical Diagnostics

    Cell Culture

    Immuno-Oncology

    Genetics

    Geography

    North America60%

    Europe26%

    Asia8%

    South America2%

    Oceania1%

    Africa1%

    Registration Source

    Website Visitors99%

    WAVE Newsletter Promotion1%

    Job Title

    Scientist16%

    Research Scientist15%

    Executive14%

    Student13%

    Educator/Faculty9%

    Post Doc8%

    Medical Doctor/Specialist6%

    Facility/Department Manager6%

    Lab Management3%

    Clinical Laboratory Scientist2%

    Medical Laboratory Technician2%

    Marketing/Sales2%

    Biologist1%

    Organization

    Academic Institution9%

    Research Institute9%

    Biotech Company9%

    Pharmaceutical Company5%

    Hospital4%

    Medical School4%

    Life Science Company3%

    Clinical Laboratory3%

    Medical Center2%

    Government2%

    Non-Profit Organization2%

    Consultant1%

    Industrial Company1%

    Contract Research Organization (Cro)1%

    Other2%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more